IMPROVED METHODS FOR MONITORING IMMUNE STATUS OF A SUBJECT

(19)

(11)

EP 3 402 515 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	08.12.2021 Bulletin 2021/49

(45)	Mention of the grant of the patent:
	11.08.2021 Bulletin 2021/32

(21)	Application number: 17738918.6

(22)	Date of filing: 12.01.2017

(51)

International Patent Classification (IPC):

A61K 39/395^(2006.01)
C12N 15/12^(2006.01)
G01N 33/68^(2006.01)

C07K 16/28^(2006.01)
G01N 33/53^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	C07K 16/2878; G01N 33/5091; G01N 33/6893

(86)	International application number:
	PCT/US2017/013169

(87)	International publication number:
	WO 2017/123741 (20.07.2017 Gazette 2017/29)

(54)	IMPROVED METHODS FOR MONITORING IMMUNE STATUS OF A SUBJECT VERBESSERTE VERFAHREN ZUR ÜBERWACHUNG DES IMMUNSTATUS EINER PERSON MÉTHODES AMÉLIORÉES POUR SURVEILLER L'ÉTAT IMMUNITAIRE D'UN SUJET

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

12.01.2016 US 201662277801 P
26.02.2016 US 201662300708 P

(43)	Date of publication of application:
	21.11.2018 Bulletin 2018/47

(60)	Divisional application:
	21190326.5

(73)	Proprietor: ONCOTRACKER, INC.
	West Hollywood, CA 90069 (US)

(72)	Inventor:
	BERENSON, James Richard Beverly Hills, CA 90210 (US)

(74)	Representative: Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
	Ganghoferstraße 68 B 80339 München 80339 München (DE)

(56)

References cited: :

EP-A1- 2 762 496
WO-A1-2014/124280
WO-A2-2010/104949
US-A1- 2014 193 433

WO-A1-2014/068079
WO-A1-2015/166073
US-A1- 2009 191 203
US-A1- 2014 220 014

ERIC SANCHEZ ET AL: "Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival", BRITISH JOURNAL OF HAEMATOLOGY, vol. 158, no. 6, 18 July 2012 (2012-07-18) , pages 727-738, XP055186278, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.2012.09241.x -& Eric Sanchez: "SUPPLEMENTAL METHODS", , 1 September 2012 (2012-09-01), XP055591762, Retrieved from the Internet: URL:https://onlinelibrary.wiley.com/action /downloadSupplement?doi=10.1111/j.1365-214 1.2012.09241.x&file=bjh9241-sup-0001-FigS1 -S4-TableS1.pdf [retrieved on 2019-05-24]
B. P. O'CONNOR: "BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 199, no. 1, 1 January 2003 (2003-01-01), pages 91-98, XP055011791, ISSN: 0022-1007, DOI: 10.1084/jem.20031330
HAMBLIN ET AL.: 'The Immunodeficiency of Chronic Lymphocytic Leukaemia' BRITISH MEDICAL BULLETIN vol. 87, 27 August 2007, pages 49 - 62, XP055399470

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).